|
|
Developing Optimal Strategies for Reducing Morbidity in Patients with Non-Cystic Fibrosis Bronchiectasis
This case-based morbidity and mortality review (MMR) assesses the negative implications of suboptimal therapeutic management for patients with non-cystic fibrosis bronchiectasis. Cases and expert discussion focus on ensuring a prompt and accurate diagnosis of bronchiectasis, understanding the benefits of high frequency chest wall oscillation (HFCWO), and identifying patients who can benefit from HFCWO. |
|
|
Addressing Key Questions About BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma
ACTIVITY DESCRIPTION
Though treatment advances have improved outcomes for most patients, MM remains an incurable disease characterized by continuous relapse. However, the treatment landscape for relapsed/refractory MM (RRMM) has expanded in recent years, and patients who relapse and/or become refractory to initial therapies are benefiting from the increasing availability of a diverse range of novel agents, including B-cell maturation antigen (BCMA)"targeted immunotherapies. These agents ... |
|
|
Unmasking Multiple Myeloma and Its Precursor Conditions in Primary Care
For multiple myeloma (MM) patients to receive the most appropriate care, a quick and accurate diagnosis is paramount. This is especially the case for Black patients, as diagnosis has historically been slower in Black patients"even though MM is twice as common in Black Americans than in White Americans. Additionally, MM precursor conditions such as monoclonal gammopathy of undetermined significance are seen more frequently in Black Americans than in White Americans. Primary care providers ... |
|